March 2, 2022 Price forecast | 2 weeks: 4.16% | 1 month: 3.21% | 3 months: 5.42%

SNSE stock forecast

Our latest prediction for Sensei Biotherapeutics Inc's stock price was made on the March 2, 2022 when the stock price was at 3.28$.

In the short term (2weeks), SNSE's stock price should outperform the market by 4.16%. During that period the price should oscillate between -11.78% and +25.69%.

In the medium term (3months), SNSE's stock price should outperform the market by 5.42%. During that period the price should oscillate between -45.48% and +65.58%.

Create a solid portfolio with SNSE

Add SNSE to your portfolio and optimize it!

About Sensei Biotherapeutics Inc

Sensei Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company has developed a proprietary bacteriophage-based platform, ImmunoPhage™, that enables the rapid generation of immune activating therapeutic agents that fully engage the immune system. Using the ImmunoPhage™ platform, Sensei is developing a library of ImmunoPhage, called Phortress™, to target multiple tumor-associated antigens to create a personalized yet off-the-shelf cocktail approach for treating cancer patients. The platform enables efficient, scalable and cost-effective manufacturing to support all of Sensei’s clinical programs. The company’s most advanced immunotherapy, SNS-301, a first-in-class ImmunoPhage™ targeting the tumor antigen Aspartyl beta Hydroxylase (ASPH), is currently in a Phase 1/2 clinical trial in patients with advanced Squamous Cell Carcinoma of the Head and Neck. Earlier stage programs include SNS-401, a ImmunoPhage™ cocktail for the treatment of Merkel Cell Carcinoma, and SNS-VISTA, an antibody-based therapeutic targeting an immune checkpoint gene that inhibits anti-tumor immune responses called V-domain Ig suppressor of T cell activation (VISTA).

At the moment the company doesn't generate any revenue.

On its last earning announcement, the company reported a loss of -1.33$ per share.

The book value per share is -1.69$

Sensei Biotherapeutics Inc website

Three months stock forecastMarch 2, 2022


Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
- - -37M - -37M -1.33 - - 28M -1.69 -30M -2M -32M